A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
Effective SARS-CoV-2 antiviral drugs are desperately needed. The SARS-CoV-2 main protease (Mpro) appears as an attractive target for drug development. We show that the existing pharmacopeia contains many drugs with potential for therapeutic repurposing as selective and potent inhibitors of SARS-CoV-...
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
Public Library of Science (PLoS)
2021-01-01
|
| Seri Bilgileri: | PLoS ONE |
| Online Erişim: | https://doi.org/10.1371/journal.pone.0245962 |